Suppr超能文献

阿尔茨海默病中脑蛋白的定性和定量比较

Qualitative and quantitative comparison of brain proteins in Alzheimer's disease.

作者信息

Buee L, Laine A, Delacourte A, Flament S, Han K K

机构信息

Unité No. 16 INSERM, Laboratoire de Neurosciences, Lille, France.

出版信息

Biol Chem Hoppe Seyler. 1989 Nov;370(11):1229-34. doi: 10.1515/bchm3.1989.370.2.1229.

Abstract

In human brain extracts, most proteins of pathological interest in Alzheimer's disease are insoluble and their analysis is often performed on denatured and reduced samples by immunoblotting after electrophoresis on polyacrylamide gel in presence of sodium dodecyl sulfate. Because we needed to accurately compare the concentration of several proteins in brain extracts to investigate the etiology of the disease, the quantitative aspect of immunoblotting was assessed and the results compared for a soluble component with those obtained by electroimmunoassay. Glial fibrillary acidic protein (GFAP) and Tau proteins were analysed by immunoblotting in brain homogenates treated with the Laemmli sample buffer from 10 control and 25 Alzheimer's disease brains. The linearity of densitometric measures of dilutions for one given sample was demonstrated. A 8 to 16-fold GFAP increase in Alzheimer brain was established. With regard to Tau proteins it was possible to show the presence of two pathological Tau variants (Tau 64 and 69) in all the Alzheimer brain homogenates, furthermore, the amount of Tau 64 and 69 was proportional to the presence of neurofibrillary degeneration. As far as alpha 1-antichymotrypsin is concerned, we showed, in a second set of brain samples (14 control and 12 Alzheimer brains), discrepancies between the results obtained by immunoblotting and by electroimmunoassay while for a given sample linearity of immunoblotting measures of dilutions of this sample was demonstrated. Quantitation by immunoblotting of such components which can be quantified using other procedures is uncertain whereas the interest of immunoblotting is undoubted for the insoluble proteins in the brain extracts.

摘要

在人脑提取物中,阿尔茨海默病中大多数具有病理学意义的蛋白质是不溶性的,对它们的分析通常是在含有十二烷基硫酸钠的聚丙烯酰胺凝胶上进行电泳后,通过免疫印迹法对变性和还原的样品进行。由于我们需要准确比较脑提取物中几种蛋白质的浓度以研究疾病的病因,因此评估了免疫印迹法的定量方面,并将可溶性成分的结果与通过电免疫测定法获得的结果进行了比较。用来自10个对照和25个阿尔茨海默病患者大脑的Laemmli样品缓冲液处理脑匀浆后,通过免疫印迹法分析胶质纤维酸性蛋白(GFAP)和Tau蛋白。证明了给定样品稀释度的光密度测量的线性。确定了阿尔茨海默病大脑中GFAP增加了8至16倍。关于Tau蛋白,有可能在所有阿尔茨海默病大脑匀浆中显示出两种病理性Tau变体(Tau 64和69)的存在,此外,Tau 64和69的量与神经原纤维变性的存在成正比。就α1-抗糜蛋白酶而言,我们在第二组脑样品(14个对照和12个阿尔茨海默病大脑)中显示,免疫印迹法和电免疫测定法获得的结果之间存在差异,同时证明了给定样品该样品稀释度的免疫印迹测量的线性。通过免疫印迹法对可以使用其他程序进行定量的此类成分进行定量是不确定的,而免疫印迹法对于脑提取物中的不溶性蛋白质的重要性是毫无疑问的。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验